AP2203A - Peptide derivative fusion inhibitors of HIV infection. - Google Patents

Peptide derivative fusion inhibitors of HIV infection.

Info

Publication number
AP2203A
AP2203A AP2005003291A AP2005003291A AP2203A AP 2203 A AP2203 A AP 2203A AP 2005003291 A AP2005003291 A AP 2005003291A AP 2005003291 A AP2005003291 A AP 2005003291A AP 2203 A AP2203 A AP 2203A
Authority
AP
ARIPO
Prior art keywords
hiv infection
peptide derivative
fusion inhibitors
derivative fusion
inhibitors
Prior art date
Application number
AP2005003291A
Other languages
English (en)
Other versions
AP2005003291A0 (en
Inventor
Dong Xie
He Jiang
Original Assignee
Frontier Biotechnologies Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frontier Biotechnologies Co Ltd filed Critical Frontier Biotechnologies Co Ltd
Publication of AP2005003291A0 publication Critical patent/AP2005003291A0/xx
Application granted granted Critical
Publication of AP2203A publication Critical patent/AP2203A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2005003291A 2002-09-24 2003-09-23 Peptide derivative fusion inhibitors of HIV infection. AP2203A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41279702P 2002-09-24 2002-09-24
PCT/US2003/029815 WO2004029201A2 (en) 2002-09-24 2003-09-23 Peptide derivative fusion inhibitors of hiv infection

Publications (2)

Publication Number Publication Date
AP2005003291A0 AP2005003291A0 (en) 2005-06-30
AP2203A true AP2203A (en) 2011-01-31

Family

ID=32043189

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003291A AP2203A (en) 2002-09-24 2003-09-23 Peptide derivative fusion inhibitors of HIV infection.

Country Status (15)

Country Link
US (3) US7575750B2 (OSRAM)
EP (1) EP1542718B1 (OSRAM)
JP (2) JP5385497B2 (OSRAM)
CN (1) CN1327897C (OSRAM)
AP (1) AP2203A (OSRAM)
AU (2) AU2003275116A1 (OSRAM)
BR (1) BR0314657A (OSRAM)
CA (1) CA2500248C (OSRAM)
CR (1) CR7806A (OSRAM)
EA (1) EA007918B1 (OSRAM)
ES (1) ES2558680T3 (OSRAM)
IL (1) IL167527A (OSRAM)
NZ (1) NZ539539A (OSRAM)
WO (1) WO2004029201A2 (OSRAM)
ZA (1) ZA200503118B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1479691T3 (da) 2001-05-31 2007-03-12 John Erickson Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
AU2003275116A1 (en) * 2002-09-24 2004-04-19 Frontier Biotechnologies Co., Ltd Peptide derivative fusion inhibitors of hiv infection
CN100455594C (zh) * 2005-12-14 2009-01-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
CN1793170A (zh) * 2005-12-14 2006-06-28 中国人民解放军军事医学科学院生物工程研究所 抑制hiv病毒融合的多肽及其用途
EP1976876A4 (en) * 2005-12-22 2010-01-13 Conjuchem Biotechnologies Inc PROCESS FOR PRODUCING PREFORMED ALBUMIN CONJUGATES AND THERAPEUTIC AGENT
WO2008144590A2 (en) * 2007-05-16 2008-11-27 Conjuchem Biotechnologies Inc. Long lasting modified antifusogenic peptide for preventing hiv infection
WO2012022040A1 (zh) * 2010-08-19 2012-02-23 清华大学 Hiv-1病毒膜融合抑制剂及其应用
CN103664701A (zh) * 2013-11-29 2014-03-26 成都普康生物科技有限公司 [2-[2-(Fmoc-氨基)乙氧基]乙氧基]乙酸合成路线
JP2022543956A (ja) * 2019-05-07 2022-10-17 フロンティア バイオテクノロジーズ インク． 安定なアルブビルチド組成物
CA3183791A1 (en) * 2020-06-28 2022-01-06 Zvika GRANOT Neutrophil-binding peptides
CN115025218B (zh) * 2021-07-30 2025-03-28 前沿生物药业(南京)股份有限公司 联用治疗人类免疫缺陷病毒的活性组合及其应用
WO2024238349A1 (en) * 2023-05-12 2024-11-21 Frontier Medicines Corporation Identification and characterization of protein sites

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069902A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting fusion peptide inhibitors or viral infection
WO2000069911A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US3791667A (en) * 1972-05-04 1974-02-12 H Haviland Retractable vehicle passenger cushioning system
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
CA2106314A1 (en) 1991-04-05 1992-10-06 John P. Burnier Platelet aggregation inhibitors having high specification for gpiibiiia
US5624902A (en) 1995-06-07 1997-04-29 Torrey Pines Institute For Molecular Studies Peptide inhibitors of calmodulin
US6475491B1 (en) * 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
US6268479B1 (en) 1997-03-12 2001-07-31 The Trustees Of Columbia University In The City Of New York Intracellular amyloid-beta peptide binding (ERAB) polypeptide
US6281331B1 (en) 1998-03-23 2001-08-28 Trimeris, Inc. Methods and compositions for peptide synthesis
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
JP4209086B2 (ja) * 1999-05-17 2009-01-14 コンジュケム バイオテクノロジーズ インコーポレイテッド 長期持続性抗新脈管形成ペプチド
EP1623994A3 (en) * 1999-05-17 2008-07-16 ConjuChem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6750008B1 (en) * 1999-07-09 2004-06-15 Trimeris, Inc. Methods and compositions for inhibition of membrane fusion-associated events, including HIV transmission
CN1172717C (zh) * 2000-08-18 2004-10-27 清华大学 一种治疗艾滋病的药物及其制备方法
AU2003275116A1 (en) * 2002-09-24 2004-04-19 Frontier Biotechnologies Co., Ltd Peptide derivative fusion inhibitors of hiv infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069902A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting fusion peptide inhibitors or viral infection
WO2000069911A1 (en) * 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting insulinotropic peptides

Also Published As

Publication number Publication date
EA200500533A1 (ru) 2005-12-29
JP2006505536A (ja) 2006-02-16
US20050089840A1 (en) 2005-04-28
JP2010209097A (ja) 2010-09-24
IL167527A (en) 2013-12-31
EP1542718A2 (en) 2005-06-22
BR0314657A (pt) 2005-08-02
US20110003735A1 (en) 2011-01-06
CA2500248A1 (en) 2004-04-08
US7575750B2 (en) 2009-08-18
WO2004029201A2 (en) 2004-04-08
CA2500248C (en) 2013-03-19
AU2003275116A1 (en) 2004-04-19
AU2010200823A1 (en) 2010-03-25
AP2005003291A0 (en) 2005-06-30
EA007918B1 (ru) 2007-02-27
ZA200503118B (en) 2006-11-29
EP1542718A4 (en) 2011-04-06
ES2558680T3 (es) 2016-02-08
US20140187476A1 (en) 2014-07-03
WO2004029201A3 (en) 2004-08-12
AU2010200823B2 (en) 2011-12-15
JP5385497B2 (ja) 2014-01-08
US8470527B2 (en) 2013-06-25
NZ539539A (en) 2006-11-30
EP1542718B1 (en) 2015-11-11
CR7806A (es) 2007-09-07
CN1327897C (zh) 2007-07-25
CN1668330A (zh) 2005-09-14

Similar Documents

Publication Publication Date Title
AU2003259155A1 (en) Pharmaceutical compositions comprising hepatitis c viral protease inhibitors
AU2003248872A1 (en) Hiv integrase inhibitors
AU2003224725A1 (en) Hiv therapeutic
AU2003264038A1 (en) Combination pharmaceutical agents as inhibitors of hcv replication
EP1406875A4 (en) N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION
AU2001234088A1 (en) TNF-alpha inhibitors
AU2001277967A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
EP1542718A4 (en) FUSION INHIBITORS AGAINST HIV INFECTION DERIVED FROM PEPTIDES
AU2003295427A1 (en) Flaviviris fusion inhibitors
AU2003269984A1 (en) Protease inhibitors
AU2001232245A1 (en) Tnf- alpha inhibitors
AU2003225394A1 (en) Necktie wearing-device
AU2003240974A1 (en) Human prolactin antagonist-angiogenesis inhibitor fusion proteins
AU2002342682A1 (en) Protease inhibitors
EP1409463A4 (en) N-HETEROCYCLIC INHIBITORS OF TNF-ALPHA EXPRESSION
AU2003244347A1 (en) Angiogenesis inhibitors
AU2003287325A1 (en) N-cycloalkylglycines as hiv protease inhibitors
AU2003263738A1 (en) Protease inhibitors
PL370348A1 (en) Preparation of hiv protease inhibitors
AU2003235205A1 (en) Preventives for hiv infection
AU2003304496A1 (en) Protease inhibitors
PL355466A1 (en) Syringe for independent first aid purposes
AU2003221324A1 (en) Angiogenesis inhibitors
AU2002350322A1 (en) Inhibitors of hepatitis c virus protease
AU2003229503A1 (en) Genetic vaccine against rna-viral infections